Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Twist Bioscience's Enterprise Value is €5,855.4 Mil.
Twist Bioscience's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €-118.7 Mil. Therefore, Twist Bioscience's EV-to-EBIT ratio for today is -49.33.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Twist Bioscience's Enterprise Value is €5,855.4 Mil.
Twist Bioscience's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €-96.9 Mil. Therefore, Twist Bioscience's EV-to-EBITDA ratio for today is -60.45.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Twist Bioscience's Enterprise Value is €5,855.4 Mil.
Twist Bioscience's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was €371.4 Mil. Therefore, Twist Bioscience's EV-to-Revenue ratio for today is 15.76.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Twist Bioscience's Enterprise Value is €5,855.4 Mil.
Twist Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €-80.0 Mil. Therefore, Twist Bioscience's EV-to-FCF ratio for today is -73.22.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Twist Bioscience (MIL:1TWST) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Twist Bioscience's current Enterprise Value is €5,855.4 Mil.
Twist Bioscience's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-118.7 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Twist Bioscience's current Enterprise Value is €5,855.4 Mil.
Twist Bioscience's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-96.9 Mil.
Twist Bioscience's current Enterprise Value is €5,855.4 Mil.
Twist Bioscience's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €371.4 Mil.
Twist Bioscience's current Enterprise Value is €5,855.4 Mil.
Twist Bioscience's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-45.5 Mil.
Twist Bioscience's current Enterprise Value is €5,855.4 Mil.
Twist Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-80.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Twist Bioscience Enterprise Value Related Terms
Twist Bioscience Enterprise Value Historical Data
* Premium members only.
The historical data trend for Twist Bioscience's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1TWST vs BLLN, SHC, RDNT: Enterprise Value Comparison
For the Diagnostics & Research subindustry, Twist Bioscience's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Twist Bioscience Enterprise Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Twist Bioscience's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Twist Bioscience's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Twist Bioscience's Enterprise Value for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of €5,855.4 Mil mean?
Twist Bioscience (MIL:1TWST) has a Enterprise Value of €5,855.4 Mil as of Aug. 07, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Twist Bioscience and its competitors.
Is Twist Bioscience's Enterprise Value too high?
Twist Bioscience's current Enterprise Value is €5,855.4 Mil. Overall, Twist Bioscience has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Twist Bioscience's Enterprise Value compare to BLLN and SHC?
Twist Bioscience's Enterprise Value of €5,855.4 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Diagnostics & Research company?
A good Enterprise Value depends on the Medical Diagnostics & Research industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Twist Bioscience and its competitors. Twist Bioscience's current Enterprise Value is €5,855.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Twist Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Twist Bioscience (MIL:1TWST) is currently considered Significantly Overvalued. The stock's GF Value™ is €46.60, compared to a current price of €97.44 — trading 109.1% above its estimated fair value. The current Enterprise Value is €5,855.4 Mil. Twist Bioscience's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Twist Bioscience (MIL:1TWST), the current Enterprise Value is €5,855.4 Mil as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Twist Bioscience (MIL:1TWST) Overvalued in 2026?
Based on GuruFocus' analysis, Twist Bioscience stock appears to be overvalued.
The current stock price of €97.44 is trading 109.1% above its estimated GF Value™ of €46.60.
GuruFocus considers Twist Bioscience to be Significantly Overvalued.
Key valuation signals for MIL:1TWST:
Enterprise Value: €5,855.4 Mil
GF Value™: €46.60 vs. price of €97.44 (109.1% above fair value)
No single metric tells the full story. See the MIL:1TWST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
47GF Score
Get the complete analysis for MIL:1TWST
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1TWST has been successfully added to your 
